A Phase I Study Combining NeoVax, a Personalized NeoAntigen Cancer Vaccine, With Ipilimumab to Treat High-risk Renal Cell Carcinoma

Trial Profile

A Phase I Study Combining NeoVax, a Personalized NeoAntigen Cancer Vaccine, With Ipilimumab to Treat High-risk Renal Cell Carcinoma

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 09 Nov 2016

At a glance

  • Drugs Ipilimumab (Primary) ; NEO-PV 01 (Primary) ; Poly ICLC (Primary)
  • Indications Carcinoma; Renal cell carcinoma
  • Focus Adverse reactions
  • Most Recent Events

    • 09 Nov 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top